Because of AD’s long preclinical phase in which amyloid-β and tau aggregate in the absence of symptoms2–4, biomarker-based disease staging can identify early changes in AD long before they can be reliably captured by cognitive decline. The gene discussed is MAPT; the disease is Alzheimer disease.